ConductScience.org, home

Paper29948616

IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients.

Vuletić A and 6 others. Pathol Oncol Res, 2020. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients. Papers, record 29948616. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29948616

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients.
PubMed
Journal
Pathol Oncol Res
PubMed
Year
2020
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
1.24
iCite
Revised in PubMed
2026-01-27
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vuletić AAnahttps://orcid.org/0000-0003-2207-8215
2Jovanić IIrena
3Jurišić VVladimir
4Milovanović ZZorka
5Nikolić SSrđan
6Spurnić IIgor
7Konjević GGordana

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Interleukin-15Major topic
Interleukin-2Major topic
Lymph NodesMajor topic
Lymphocyte SubsetsMajor topic
MelanomaMajor topic
Skin NeoplasmsMajor topic
CD8-Positive T-Lymphocytes
Female
Humans
Killer Cells, Natural
Male
NK Cell Lectin-Like Receptor Subfamily K
Natural Killer T-Cells
Receptors, KIR2DL1
Receptors, KIR2DL3
Cutaneous Malignant Melanoma

Source PubMed

Download CSV of topics

References37

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
117953420Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy.Cancer Treat Res2007https://conductscience.org/library/papers/17953420PubMed
220956026IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion.Immunobiology2011https://conductscience.org/library/papers/20956026PubMed
319711124Distribution of several activating and inhibitory receptors on CD3-CD16+ NK cells and their correlation with NK cell function in healthy individuals.J Membr Biol2009https://conductscience.org/library/papers/19711124PubMed
421212348Innate or adaptive immunity? The example of natural killer cells.Science2011https://conductscience.org/library/papers/21212348PubMed
525380182In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15.Melanoma Res2015https://conductscience.org/library/papers/25380182PubMed
621467299Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance.Sci Signal2011https://conductscience.org/library/papers/21467299PubMed
71692763Lymphocyte subset alterations in nodes regional to human melanoma.Cancer Res1990https://conductscience.org/library/papers/1692763PubMed
820172016Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.Exp Hematol2010https://conductscience.org/library/papers/20172016PubMed
918280748Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation.Cytokine2008https://conductscience.org/library/papers/18280748PubMed
1018713998Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptors.J Immunol2008https://conductscience.org/library/papers/18713998PubMed
1120693852Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer.Cancer J2010https://conductscience.org/library/papers/20693852PubMed
1225472612Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients.Nat Commun2014https://conductscience.org/library/papers/25472612PubMed
1318657862NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways.Mol Immunol2008https://conductscience.org/library/papers/18657862PubMed
1422349515Melanoma-induced immunosuppression and its neutralization.Semin Cancer Biol2012https://conductscience.org/library/papers/22349515PubMed
1526597610Common gamma chain cytokines in combinatorial immune strategies against cancer.Immunol Lett2016https://conductscience.org/library/papers/26597610PubMed
1626374324Natural killer cell receptors: alterations and therapeutic targeting in malignancies.Immunol Res2016https://conductscience.org/library/papers/26374324PubMed
1714698281The double life of NK receptors: stimulation or co-stimulation?Trends Immunol2004https://conductscience.org/library/papers/14698281PubMed
1821898152Regulation of immune cell function and differentiation by the NKG2D receptor.Cell Mol Life Sci2011https://conductscience.org/library/papers/21898152PubMed
199774227Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2.Naunyn Schmiedebergs Arch Pharmacol1998https://conductscience.org/library/papers/9774227PubMed
2011504744Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.J Clin Oncol2001https://conductscience.org/library/papers/11504744PubMed

See all 37 referencesDownload CSV of references

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
42968599Immunogenetic Signature of the MICA-129 Val/Val Genotype Associated With Metastasis in Melanoma.J Immunol Res2026https://conductscience.org/library/papers/42968599PubMed
41346595Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment.Front Immunol2025https://conductscience.org/library/papers/41346595PubMed
40636453The Multifaceted Role of the IL-2 Cytokine Family in Melanoma: Mechanisms, Therapeutic Implications, and Immune Modulation.J Immunol Res2025https://conductscience.org/library/papers/40636453PubMed
39907091Evaluating Predictors of Quality in Liver NK Cells Among Deceased Donors.Cell Transplant2024https://conductscience.org/library/papers/39907091PubMed
39628491Molecular cloning, expression analysis, and functional characterization of an interleukin-15 like gene in common carp (Cyprinus carpio L.).Front Immunol2024https://conductscience.org/library/papers/39628491PubMed
38506480Cancer immunity by tissue-resident type 1 innate lymphoid cells and killer innate-like T cells.Immunol Rev2024https://conductscience.org/library/papers/38506480PubMed
38255242Mice Generated with Induced Pluripotent Stem Cells Derived from Mucosal-Associated Invariant T Cells.Biomedicines2024https://conductscience.org/library/papers/38255242PubMed
38106519Suppression of NK Cell Activation by JAK3 Inhibition: Implication in the Treatment of Autoimmune Diseases.J Immunol Res2023https://conductscience.org/library/papers/38106519PubMed
37949944Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer.Cancer Gene Ther2023https://conductscience.org/library/papers/37949944PubMed
37696894Double-edged sword: γδ T cells in mucosal homeostasis and disease.Exp Mol Med2023https://conductscience.org/library/papers/37696894PubMed
37626875Reduction of Ca2+ Entry by a Specific Block of KCa3.1 Channels Optimizes Cytotoxic Activity of NK Cells against T-ALL Jurkat Cells.Cells2023https://conductscience.org/library/papers/37626875PubMed
37221555Targeting oral tumor microenvironment for effective therapy.Cancer Cell Int2023https://conductscience.org/library/papers/37221555PubMed
37086778Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression.J Adv Res2024https://conductscience.org/library/papers/37086778PubMed
36936961The application of Interleukin-2 family cytokines in tumor immunotherapy research.Front Immunol2023https://conductscience.org/library/papers/36936961PubMed
36769064Natural Killer T-like Cells: Immunobiology and Role in Disease.Int J Mol Sci2023https://conductscience.org/library/papers/36769064PubMed
36686835Contribution of natural killer cells in innate immunity against colorectal cancer.Front Oncol2022https://conductscience.org/library/papers/36686835PubMed
36590594IL-15 induced bystander activation of CD8+ T cells may mediate endothelium injury through NKG2D in Hantaan virus infection.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/36590594PubMed
35765872Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used.Ann Lab Med2022https://conductscience.org/library/papers/35765872PubMed
35378905The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs).J Immunol Res2022https://conductscience.org/library/papers/35378905PubMed
33467134EZH1/2 Inhibitors Favor ILC3 Development from Human HSPC-CD34+ Cells.Cancers (Basel)2021https://conductscience.org/library/papers/33467134PubMed

See all 22 cited byDownload CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
IL153600PubTator's text mininghttps://conductscience.org/library/genes/3600NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
KIR2DL23803PubTator's text mininghttps://conductscience.org/library/genes/3803NCBI Gene
KIR2DS13806PubTator's text mininghttps://conductscience.org/library/genes/3806NCBI Gene
KLRK122914PubTator's text mininghttps://conductscience.org/library/genes/22914NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29948616

GET https://conductscience.org/api/papers/v1/29948616/references?page=2